Clinical Trials Logo

Filter by:
NCT ID: NCT01352442 Completed - Presbyopia Clinical Trials

Safety and Effectiveness of the AcuFocus Corneal Inlay ACI7000PDT in Presbyopes

Start date: May 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if the AcuFocus Corneal Inlay ACI 7000PDT will provide an effective method of for the correction of presbyopia in patients who have normal distance vision but need correction such as glasses or contact lenses to see clearly at near.

NCT ID: NCT01352338 Completed - Multiple Myeloma Clinical Trials

Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)

REPEAT
Start date: August 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Study Phase: phase 1 and phase 2 Objective: Evaluation of the effect of lenalidomide, cyclophophamide and prednisone (REP) in patients with relapsed multiple myeloma previously treated with lenalidomide Study design: prospective, multicenter, non-randomized

NCT ID: NCT01351792 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease

A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)

FAIR
Start date: September 2011
Phase: Phase 3
Study type: Interventional

The purpose of the present study is to demonstrate the higher efficacy of small particles Foster® 100/6 (two puffs b.i.d.) versus large particles Symbicort® 200/6 (two inhalations b.i.d.), in terms of residual volume reduction over a 12-week treatment period in Chronic Obstructive Pulmonary Disease (COPD) patients.

NCT ID: NCT01351415 Completed - Clinical trials for Non-Squamous Non-Small Cell Lung Cancer

A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Start date: June 25, 2011
Phase: Phase 3
Study type: Interventional

This open-label, randomized, multicenter study will evaluate the efficacy and safety of bevacizumab (Avastin) in combination with standard of care (SOC) treatment in participants with advanced non-squamous NSCLC. Participants will be enrolled at documentation of progression of disease (PD) after 4-6 cycles of first-line treatment with bevacizumab plus a platinum doublet-containing therapy and a minimum of two cycles of bevacizumab maintenance treatment prior to PD. Participants will be randomly assigned to one of two treatment arms to receive either bevacizumab plus SOC treatment or SOC treatment alone.

NCT ID: NCT01351103 Active, not recruiting - Pancreatic Cancer Clinical Trials

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Start date: December 1, 2011
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that have progressed despite standard therapy or for which no effective standard therapy exists

NCT ID: NCT01350960 Terminated - Clinical trials for Hypercholesterolemia

Multiple Ascending Dose Study of SPC5001 in Treatment of Healthy Subjects and Subjects With FH

Start date: May 2011
Phase: Phase 1
Study type: Interventional

The purpose is to study Safety and Tolerability.

NCT ID: NCT01348828 Completed - Clinical trials for Abdominal Aortic Aneurysm

Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System

Start date: October 19, 2011
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the safety and feasibility of the Endologix Fenestrated Stent Graft System for the endovascular repair of juxtarenal or pararenal aortic aneurysms.

NCT ID: NCT01348191 Completed - Clinical trials for Thyrothrophin Receptor in Myometrium Tissue

Detection of Thyrotrophin Receptor in Human Myometrium

Start date: November 2011
Phase: N/A
Study type: Observational

It has been recognized for many decades that high thyrotrophin (TSH) levels in pregnant women are associated with poor obstetric outcome. Also, there is evidence that high TSH is related to fetal position at term, including breech which in turn is associated with obstetric complications. However, the mechanism behind remains to be elucidated. The current project is of basic-fundamental nature. It is used to better understand basis physiological processes. As in many other studies of similar basic nature, few numbers are always included. If a TSH receptor will be detected, future randomized controlled trials (RCT) might be worthwhile with large numbers of women who will be treated with thyroxine to possibly prevent abnormal fetal position during normal pregnancy. The aim of the current study is to evaluate whether a TSH receptor can be demonstrated in human myometrium. If so, the pathophysiology of high TSH in relation to obstetric outcome will become more clear. Furthermore, the aim is to test the myometrium in vitro for its relaxation and contractility and for the conductance of electropotentials.

NCT ID: NCT01347827 Completed - Clinical trials for Coronary Artery Bypass Grafting

Tissue Oxygenation During Heart Surgery

Start date: June 2011
Phase:
Study type: Observational

The goal of this study is to determine if off-pump CABG surgery is associated with better cerebral tissue oxygenation when compared with on-pump CABG. In addition, the investigators would like to compare the results of two different monitors of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation (ScvO2). Finally, the investigators aim to determine if duration and extent of cerebral oxygen desaturation predict outcome variables such as postoperative cognitive performance.

NCT ID: NCT01347580 Completed - Clinical trials for Myocardial Infarction

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

ATLANTIC
Start date: September 2011
Phase: Phase 4
Study type: Interventional

The aim of this study is to determine whether initiation of ticagrelor as early as in the ambulance setting leads to a rapid reperfusion of the infarct-related artery therefore facilitating the Percutaneous Coronary Intervention (PCI) and optimizing the outcome for the patient. The study will assess the efficacy and safety of pre-hospital compared to in-hospital administration of ticagrelor in co-administration with aspirin, on restoring the blood flow in the occluded heart artery and improving the myocardial perfusion in patients suffering from myocardial infarction and planned to have a PCI. Patients can be randomised in either one of the 2 arms: re-hospital ticagrelor arm: Patients will receive a loading dose of 180 mg ticagrelor for the pre-hospital administration and placebo for in-hospital administration. or In-hospital ticagrelor arm: Patients will receive a placebo for pre-hospital administration and 180 mg ticagrelor loading dose for in-hospital administration. Patients are initially managed by ambulance physician/personnel in pre hospital settings. They are then transferred into a Catheterization room to undergo a PCI. After the administration of the loading dose of ticagrelor (double blind), patients will continue on ticagrelor 90 mg bid and be followed in study for 30 days post randomisation.